BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines income Statement — Total revenue ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Operations (DB)
Latest, FY2025
5,343
Period ended Dec 31, 2025
Change on a year earlier
+40.2%
3,810 in FY2024
History
12 years
Since FY2014
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Income Statement — Total revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5,343 | +40.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 3,810 | +55.0% | Form 10-K (filed 2025-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 2,459 | +73.7% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 1,416 | +20.4% | Form 10-K (filed 2023-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 1,176 | +280.8% | Form 10-K (filed 2022-02-28) ↗ |
| FY2020 | Dec 31, 2020 | 309 | -27.9% | Form 10-K (filed 2021-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 428 | +116.0% | Form 10-K (filed 2020-03-02) ↗ |
| FY2018 | Dec 31, 2018 | 198 | -16.9% | Form 10-K (filed 2019-02-28) ↗ |
| FY2017 | Dec 31, 2017 | 238 | +21,572.7% | Form 10-K (filed 2018-02-28) ↗ |
| FY2016 | Dec 31, 2016 | 1.10 | -87.5% | Form 10-K (filed 2017-03-22) ↗ |
| FY2015 | Dec 31, 2015 | 8.80 | -32.3% | Form 10-K (filed 2017-03-22) ↗ |
| FY2014 | Dec 31, 2014 | 13 | – | Form 10-K (filed 2017-03-22) ↗ |
Breakdown
What makes up income statement — total revenue ($m)
- Cost of sales — product ($M)669 · FY2025
- Gross profit ($M)4,675 · FY2025
- Research and development expense ($M)2,146 · FY2025
- Selling, general and administrative expense ($M)2,082 · FY2025
- Total operating expenses ($M)4,227 · FY2025
- Income (loss) from operations ($M)447 · FY2025
- Income (loss) before income taxes ($M)417 · FY2025
- Income tax expense ($M)130 · FY2025
- Net income (loss) ($M)287 · FY2025
- Earnings (loss) per ordinary share — Basic ($/sh)0.20 · FY2025
- Earnings (loss) per ordinary share — Diluted ($/sh)0.19 · FY2025
- Weighted-average basic ordinary shares outstanding (M)1,418 · FY2025
- Weighted-average diluted ordinary shares outstanding (M)1,475 · FY2025
Cite this data
StockData. (2026). BeOne Medicines Income Statement — Total revenue ($M) ($M), annual FY2014–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/fs_income_stmt
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.